Table 2. Incidence of grade 3–5 adverse events (occurring in >5% of patients).

Adverse event	CisPemBev, N=131, n [%]	CarPacBev, N=66, n [%]
Hematological toxicities
Neutrophil count decreased	32 [24]	42 [64]
Anemia	9 [7]	4 [6]
Platelet count decreased	8 [6]	1 [2]
Febrile neutropenia	2 [2]	6 [9]
White blood cell decreased	16 [12]	20 [30]
Non-hematological toxicities
Hyponatremia	14 [11]	6 [9]
Anorexia	9 [7]	3 [5]

CarPacBev, carboplatin + paclitaxel + bevacizumab; CisPemBev, cisplatin + pemetrexed + bevacizumab.